Telix Pharmaceuticals Limited (OTCMKTS:TLPPF – Get Free Report) shares were down 1.4% on Wednesday . The company traded as low as $7.68 and last traded at $7.68. Approximately 6,878 shares changed hands during trading, an increase of 25% from the average daily volume of 5,484 shares. The stock had previously closed at $7.79.
Telix Pharmaceuticals Stock Down 1.4%
The firm’s fifty day moving average price is $9.41 and its 200 day moving average price is $11.45.
Telix Pharmaceuticals Company Profile
Telix Pharmaceuticals is a molecularly targeted radiopharmaceutical company specializing in the development and commercialisation of diagnostic and therapeutic products for oncology and rare diseases. The company leverages radioisotopes conjugated to disease-specific targeting agents, enabling precise imaging and treatment of cancerous lesions. Telix’s portfolio includes investigational imaging compounds, such as a gallium-68-labeled prostate cancer agent, alongside therapeutic candidates that deliver beta- or alpha-emitting isotopes directly to disease sites.
Telix’s lead diagnostic program focuses on positron emission tomography (PET) imaging for prostate cancer, designed to improve detection and staging accuracy.
Featured Articles
- Five stocks we like better than Telix Pharmaceuticals
- BNZI Posts Record Q3 Revenue – See What’s Driving It.
- Washington prepares for war
- Do you know what Amazon is planning for January 1?
- Nvidia x 1,000,000
- Put $1,000 into this stock by Jan 1 [Not NVDA]
Receive News & Ratings for Telix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
